DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2024.
THIRD QUARTER 2024 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
- Net income of $0.12 per share, Nareit FFO of $0.44 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.41 per share, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 4.1%
- Increased the midpoint of both 2024 FFO as Adjusted and AFFO guidance by +$0.01 per share, and increased Total Merger-Combined Same-Store Cash (Adjusted) NOI growth guidance by +50 basis points at the midpoint
- Increased expected 2024 merger-related synergies to approximately $50 million, driven by property management internalization
- Continued strong momentum in life science with 733,000 square feet of lease executions during the third quarter and through October 24, 2024:
- Executed 465,000 square feet of lab leases during the third quarter 2024, including a 37,000 square foot lease at Gateway; achieved a positive 10% cash rent mark-to-market on renewals
- Executed 268,000 square feet of lab leases in October 2024 including 205,000 square feet at Portside and 63,000 square feet at Vantage bringing these marquee campuses to approximately 90% and 70% leased, respectively
- Signed letters of intent ("LOI") on an additional 575,000 square feet of lab leases including 33,000 square feet at Gateway bringing the development to 42% leased or committed
- Outpatient medical new and renewal lease executions totaled 3 million square feet with 89% retention and positive 10% cash rent mark-to-market on renewals, including the previously announced CommonSpirit renewal
- Commenced a $37 million, 79,000 square foot Class A outpatient medical development in Kansas City that is 100% pre-leased to HCA
- Promoted Natalia De Michele to Senior Vice President - Bay Area Market Lead and hired Claire Donegan Brown as Senior Vice President - Boston Market Lead, both reporting to Scott Bohn, Chief Development Officer and Head of Lab
- Net Debt to Adjusted EBITDAre was 5.1x for the quarter ended September 30, 2024
- On October 23, 2024, Healthpeak's Board of Directors declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 15, 2024, to stockholders of record as of the close of business on November 4, 2024
- Received the GRESB Green Star designation for the thirteenth consecutive year and recognized for leading governance and corporate impact disclosures by Governance Intelligence and IR Magazine
THIRD QUARTER COMPARISON
Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | ||||||||||||||
(in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||
Net income, diluted | $ | 85,722 | $ | 0.12 | $ | 64,048 | $ | 0.12 | |||||||
Nareit FFO, diluted | 315,824 | 0.44 | 252,566 | 0.46 | |||||||||||
FFO as Adjusted, diluted | 320,776 | 0.45 | 251,647 | 0.45 | |||||||||||
AFFO, diluted | 289,509 | 0.41 | 219,645 | 0.40 | |||||||||||
YEAR TO DATE COMPARISON
Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | ||||||||||||||
(in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||
Net income, diluted | $ | 238,057 | $ | 0.36 | $ | 233,497 | $ | 0.43 | |||||||
Nareit FFO, diluted | 797,546 | 1.17 | 730,764 | 1.32 | |||||||||||
FFO as Adjusted, diluted | 918,665 | 1.35 | 735,067 | 1.33 | |||||||||||
AFFO, diluted | 814,404 | 1.20 | 652,839 | 1.18 | |||||||||||
Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "September 30, 2024 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.
MERGER-COMBINED SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month and year-to-date Merger-Combined SS Cash (Adjusted) NOI growth.
Year-Over-Year Total Merger-Combined SS Cash (Adjusted) NOI Growth | |||||
Three Month | Year-To-Date | ||||
SS Growth % | % of SS | SS Growth % | % of SS | ||
Outpatient Medical | 3.4% | 55.0% | 3.3% | 55.1% | |
Lab | 2.8% | 35.5% | 3.1% | 35.1% | |
CCRC | 14.2% | 9.5% | 20.2% | 9.8% | |
Total Merger-Combined SS Cash (Adjusted) NOI | 4.1% | 100.0% | 4.6% | 100.0% | |
PHYSICIANS REALTY TRUST MERGER INTEGRATION
In September, Healthpeak internalized outpatient medical property management in Denver and Utah. To date, the company has completed internalization of property management in 14 markets and now internally property manages 24 million square feet.
Healthpeak now expects to achieve approximately $50 million of merger-related synergies during 2024.
LIFE SCIENCE LEASING UPDATE
During the third quarter 2024 and through October 24, 2024, Healthpeak executed lab lease agreements totaling 733,000 square feet.
- During the third quarter 2024, Healthpeak executed 465,000 square feet of lease agreements.
- From October 1 to October 24, 2024, Healthpeak executed an additional 268,000 square feet of lease agreements.
Year-to-date through October 24, 2024, Healthpeak has executed 1.7 million square feet of lab leases with an additional 575,000 square feet under signed LOIs.
Highlights of recent leasing activity at marquee projects includes:
- Portside (South San Francisco): In October, signed a 12.5-year, 205,000 square foot new lease with a private life science company.
The tenant will relocate from its current space within Healthpeak's portfolio to two full buildings on the Portside campus:
- 1100 Veterans Boulevard: Tenant improvements on the 112,500 square foot building will commence in late 2024 with occupancy expected in the third quarter of 2025.
- 1120 Veterans Boulevard: Tenant improvements on the 92,500 square foot building will commence in mid-2025 with the phase-in of approximately 31,000 square feet of occupancy in each of 2026, 2027, and 2028.
Since 2021, Healthpeak has signed or commenced 854,000 square feet of leases at Portside bringing the campus to approximately 90% leased. The only remaining availabilities on the 960,000 square foot campus are the 73,000 square foot 1140 Veterans building currently in redevelopment and a 33,000 square foot suite at 331 Oyster Point Boulevard.
Healthpeak is also under construction to refresh and modernize Portside's landscaping, entrances, and signage with improvements to pedestrian connectivity to Healthpeak's adjacent Cove campus and amenities center. Combined, The Cove and Portside campuses create a nearly 2 million square foot contiguous campus at the doorstep of South San Francisco's prestigious biotech market.
- Vantage (South San Francisco): In October, signed an 8-year, 63,000 square foot lease with a private biotech company.
The tenant will relocate from its current space within Healthpeak's portfolio after tenant improvements are completed in late 2025. The two-floor lease brings the 346,000 square foot first phase of Vantage to approximately 70% leased.
Additionally, in September, Healthpeak held the grand opening for The Hangar, a 40,000 square foot market-leading tenant amenity center on the Vantage campus. The Hangar features four unique quick-service restaurants, an artisanal coffee bar, a full-service restaurant, a bar and lounge, a fitness center, and a state-of-the-art conference and meeting space. - Gateway (Sorrento Mesa): In July, signed an 8-year, 37,000 square foot lease with a private biotech company. The lease is expected to commence in the third quarter of 2025. Additionally, in October, Healthpeak signed an LOI for 33,000 square feet with a mid-cap public biotech. Both tenants are new to the Healthpeak portfolio.
The recent leasing activity brings the Gateway development to 42% leased or committed.
LIFE SCIENCE MARKET LEADERSHIP UPDATES
Healthpeak today announced the following leadership updates, effective January 1, 2025:
- Natalia De Michele will be promoted to Senior Vice President - Bay Area Market Lead, where she will lead all aspects of Healthpeak's lab leasing, development, and asset management activities in the Bay Area. Since joining Healthpeak in 2018, Ms. De Michele has executed over six million square feet of lab leasing transactions.
- Claire Donegan Brown will join Healthpeak in January 2025 as Senior Vice President - Boston Market Lead and assume leadership of the company's Boston lab portfolio. Ms. Brown brings 12 years of leasing, development, and asset management experience within the Boston market, having formerly worked for Greatland Realty Partners, an owner and developer of lab real estate in Boston, and BXP, a publicly-traded real estate investment trust.
Mike Dorris will continue leading all aspects of Healthpeak's lab leasing, development, and asset management activities in San Diego as Senior Vice President - San Diego Market Lead. Mr. Dorris has led Healthpeak's San Diego portfolio since joining the company in 2010.
All three market leaders will report to Scott Bohn, Chief Development Officer and Head of Lab.
KANSAS CITY RESEARCH SCHOOL OF NURSING DEVELOPMENT
During the third quarter, Healthpeak added a new development to its program with HCA. The $37 million, 79,000 square foot Class A outpatient medical building is located on HCA's Research Medical Center campus, a 590-bed acute care hospital in Kansas City, Missouri. Affiliates of HCA have pre-leased 100% of the development.
CORPORATE IMPACT
Healthpeak received the GRESB Green Star designation for the thirteenth consecutive year. Healthpeak was also named a finalist by Governance Intelligence and IR Magazine for Best Proxy Statement for the fifth consecutive year and Best ESG Reporting for the third consecutive year. The Company also earned a 2024 International MarCom Gold Award for its 2023 Corporate Impact Report from the Association of Marketing and Communication Professionals (AMCP).
To learn more about Healthpeak's commitment to responsible business and view our 2023 ESG Corporate Impact Report, please visit www.healthpeak.com/corporate-impact.
DIVIDEND
On October 23, 2024, Healthpeak's Board of Directors declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 15, 2024, to stockholders of record as of the close of business on November 4, 2024.
2024 GUIDANCE
We are updating the following guidance ranges for full year 2024:
- Diluted earnings per common share from $0.27 - $0.31 to $0.40 - $0.42
- Diluted Nareit FFO per share from $1.59 - $1.63 to $1.61 - $1.63
- Diluted FFO as Adjusted per share from $1.77 - $1.81 to $1.79 - $1.81
- Diluted AFFO per share from $1.54 - $1.58 to $1.56 - $1.58
- Total Merger-Combined Same-Store Cash (Adjusted) NOI growth from 2.75% - 4.25% to 3.5% - 4.5%
These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. For additional details and assumptions, please see page 12 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for Friday, October 25, 2024, at 8:00 a.m. Mountain Time.
The conference call can be accessed in the following ways:
- Healthpeak's website: https://ir.healthpeak.com/news-events
- Webcast: https://events.q4inc.com/attendee/713594150. Joining via webcast is recommended for those who will not be asking questions.
- Telephone: The participant dial-in number is (800) 715-9871.
An archive of the webcast will be available on Healthpeak's website through October 23, 2025, and a telephonic replay can be accessed through November 1, 2024, by dialing (800) 770-2030 and entering conference ID number 95156.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate focused on healthcare discovery and delivery.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our anticipated synergies from our merger with Physicians Realty Trust (the "Merger"); (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, construction and labor costs, and unemployment; risks associated with the merger, including, but not limited to, our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Merger or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants', operators', or borrowers' ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third-party management contracts, including the additional regulation and liabilities of our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as "RIDEA"); economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our use of joint ventures that may limit our returns on and our flexibility with jointly owned investments; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; our ability to satisfy environmental, social and governance and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including the coronavirus disease (Covid), and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and any material failure, inadequacy, interruption, or security failure of that technology; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions and other factors; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the Coronavirus, Aid, Relief and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a real estate investment trust ("REIT"); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from "prohibited transactions"; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC ("Healthpeak OP") common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings.
Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Healthpeak Properties, Inc. Consolidated Balance Sheets In thousands, except share and per share data | |||||||
September 30, 2024 | December 31, 2023 | ||||||
Assets | |||||||
Real estate: | |||||||
Buildings and improvements | $ | 16,059,802 | $ | 13,329,464 | |||
Development costs and construction in progress | 830,310 | 643,217 | |||||
Land and improvements | 2,927,675 | 2,647,633 | |||||
Accumulated depreciation and amortization | (3,925,375 | ) | (3,591,951 | ) | |||
Net real estate | 15,892,412 | 13,028,363 | |||||
Loans receivable, net of reserves of $9,983 and $2,830 | 677,590 | 218,450 | |||||
Investments in and advances to unconsolidated joint ventures | 931,844 | 782,853 | |||||
Accounts receivable, net of allowance of $2,405 and $2,282 | 64,979 | 55,820 | |||||
Cash and cash equivalents | 180,430 | 117,635 | |||||
Restricted cash | 61,615 | 51,388 | |||||
Intangible assets, net | 898,379 | 314,156 | |||||
Assets held for sale, net | - | 117,986 | |||||
Right-of-use asset, net | 427,711 | 240,155 | |||||
Other assets, net | 834,806 | 772,044 | |||||
Total assets | $ | 19,969,766 | $ | 15,698,850 | |||
Liabilities and Equity | |||||||
Bank line of credit and commercial paper | $ | - | $ | 720,000 | |||
Term loans | 1,645,748 | 496,824 | |||||
Senior unsecured notes | 6,557,170 | 5,403,378 | |||||
Mortgage debt | 380,459 | 256,097 | |||||
Intangible liabilities, net | 202,857 | 127,380 | |||||
Liabilities related to assets held for sale, net | - | 729 | |||||
Lease liability | 308,277 | 206,743 | |||||
Accounts payable, accrued liabilities, and other liabilities | 749,881 | 657,196 | |||||
Deferred revenue | 903,371 | 905,633 | |||||
Total liabilities | 10,747,763 | 8,773,980 | |||||
Commitments and contingencies | |||||||
Redeemable noncontrolling interests | 1,318 | 48,828 | |||||
Common stock, $1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 699,405,171 and 547,156,311 shares issued and outstanding | 699,405 | 547,156 | |||||
Additional paid-in capital | 12,844,634 | 10,405,780 | |||||
Cumulative dividends in excess of earnings | (4,968,819 | ) | (4,621,861 | ) | |||
Accumulated other comprehensive income (loss) | (12,381 | ) | 19,371 | ||||
Total stockholders' equity | 8,562,839 | 6,350,446 | |||||
Joint venture partners | 321,949 | 310,998 | |||||
Non-managing member unitholders | 335,897 | 214,598 | |||||
Total noncontrolling interests | 657,846 | 525,596 | |||||
Total equity | 9,220,685 | 6,876,042 | |||||
Total liabilities and equity | $ | 19,969,766 | $ | 15,698,850 | |||
Healthpeak Properties, Inc. Consolidated Statements of Operations In thousands, except per share data | |||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Revenues: | |||||||||||||||
Rental and related revenues | $ | 543,251 | $ | 417,075 | $ | 1,552,065 | $ | 1,219,473 | |||||||
Resident fees and services | 142,845 | 133,808 | 422,512 | 391,076 | |||||||||||
Interest income and other | 14,301 | 5,360 | 27,884 | 16,802 | |||||||||||
Total revenues | 700,397 | 556,243 | 2,002,461 | 1,627,351 | |||||||||||
Costs and expenses: | |||||||||||||||
Interest expense | 74,105 | 50,510 | 209,922 | 147,547 | |||||||||||
Depreciation and amortization | 280,019 | 184,559 | 782,736 | 561,357 | |||||||||||
Operating | 280,279 | 232,734 | 797,835 | 677,659 | |||||||||||
General and administrative | 23,216 | 23,093 | 73,233 | 73,576 | |||||||||||
Transaction and merger-related costs | 7,134 | 36 | 122,113 | 3,098 | |||||||||||
Impairments and loan loss reserves (recoveries), net | 441 | (550 | ) | 11,346 | (156 | ) | |||||||||
Total costs and expenses | 665,194 | 490,382 | 1,997,185 | 1,463,081 | |||||||||||
Other income (expense): | |||||||||||||||
Gain (loss) on sales of real estate, net | 62,325 | - | 187,624 | 86,463 | |||||||||||
Other income (expense), net | 982 | 1,481 | 83,502 | 4,208 | |||||||||||
Total other income (expense), net | 63,307 | 1,481 | 271,126 | 90,671 | |||||||||||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 98,510 | 67,342 | 276,402 | 254,941 | |||||||||||
Income tax benefit (expense) | (1,938 | ) | (787 | ) | (18,364 | ) | (2,225 | ) | |||||||
Equity income (loss) from unconsolidated joint ventures | (3,834 | ) | 2,101 | (1,407 | ) | 6,646 | |||||||||
Net income (loss) | 92,738 | 68,656 | 256,631 | 259,362 | |||||||||||
Noncontrolling interests' share in earnings | (6,866 | ) | (4,442 | ) | (18,036 | ) | (24,297 | ) | |||||||
Net income (loss) attributable to Healthpeak Properties, Inc. | 85,872 | 64,214 | 238,595 | 235,065 | |||||||||||
Participating securities' share in earnings | (197 | ) | (166 | ) | (610 | ) | (1,568 | ) | |||||||
Net income (loss) applicable to common shares | $ | 85,675 | $ | 64,048 | $ | 237,985 | $ | 233,497 | |||||||
Earnings (loss) per common share: | |||||||||||||||
Basic | $ | 0.12 | $ | 0.12 | $ | 0.36 | $ | 0.43 | |||||||
Diluted | $ | 0.12 | $ | 0.12 | $ | 0.36 | $ | 0.43 | |||||||
Weighted average shares outstanding: | |||||||||||||||
Basic | 699,349 | 547,062 | 667,536 | 546,978 | |||||||||||
Diluted | 700,146 | 547,331 | 668,096 | 547,247 | |||||||||||
Healthpeak Properties, Inc. Funds From Operations In thousands, except per share data | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net income (loss) applicable to common shares | $ | 85,675 | $ | 64,048 | $ | 237,985 | $ | 233,497 | ||||||||
Real estate related depreciation and amortization | 280,019 | 184,559 | 782,736 | 561,357 | ||||||||||||
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 12,127 | 6,190 | 32,520 | 18,076 | ||||||||||||
Noncontrolling interests' share of real estate related depreciation and amortization | (4,534 | ) | (4,571 | ) | (13,705 | ) | (14,042 | ) | ||||||||
Loss (gain) on sales of depreciable real estate, net | (62,325 | ) | - | (187,624 | ) | (86,463 | ) | |||||||||
Noncontrolling interests' share of gain (loss) on sales of depreciable real estate, net | - | - | - | 11,546 | ||||||||||||
Loss (gain) upon change of control, net(1) | 430 | - | (77,548 | ) | (234 | ) | ||||||||||
Taxes associated with real estate dispositions(2) | (145 | ) | - | 11,512 | - | |||||||||||
Nareit FFO applicable to common shares | 311,247 | 250,226 | 785,876 | 723,737 | ||||||||||||
Distributions on dilutive convertible units and other | 4,577 | 2,340 | 11,670 | 7,027 | ||||||||||||
Diluted Nareit FFO applicable to common shares | $ | 315,824 | $ | 252,566 | $ | 797,546 | $ | 730,764 | ||||||||
Diluted Nareit FFO per common share | $ | 0.44 | $ | 0.46 | $ | 1.17 | $ | 1.32 | ||||||||
Weighted average shares outstanding - Diluted Nareit FFO | 714,715 | 554,614 | 681,128 | 554,535 | ||||||||||||
Impact of adjustments to Nareit FFO: | ||||||||||||||||
Transaction and merger-related items(3) | $ | 2,725 | $ | 49 | $ | 108,923 | $ | 2,993 | ||||||||
Other impairments (recoveries) and other losses (gains), net(4) | 441 | (602 | ) | 11,741 | 557 | |||||||||||
Restructuring and severance-related charges | - | - | - | 1,368 | ||||||||||||
Casualty-related charges (recoveries), net(5) | 1,792 | (367 | ) | 588 | (610 | ) | ||||||||||
Total adjustments | 4,958 | (920 | ) | 121,252 | 4,308 | |||||||||||
FFO as Adjusted applicable to common shares | 316,205 | 249,306 | 907,128 | 728,045 | ||||||||||||
Distributions on dilutive convertible units and other | 4,571 | 2,341 | 11,537 | 7,022 | ||||||||||||
Diluted FFO as Adjusted applicable to common shares | $ | 320,776 | $ | 251,647 | $ | 918,665 | $ | 735,067 | ||||||||
Diluted FFO as Adjusted per common share | $ | 0.45 | $ | 0.45 | $ | 1.35 | $ | 1.33 | ||||||||
Weighted average shares outstanding - Diluted FFO as Adjusted | 714,715 | 554,614 | 681,128 | 554,535 | ||||||||||||
_______________________________________ | ||
(1) | The nine months ended September 30, 2024 includes a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations. | |
(2) | The nine months ended September 30, 2024 includes non-cash income tax expense related to the sale of a 65% interest in two lab buildings in San Diego, California. | |
(3) | The three and nine months ended September 30, 2024 includes costs related to the Merger, which are primarily comprised of advisory, legal, accounting, tax, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust that were incurred during the period. These costs were partially offset by termination fee income of $4 million and $13 million for the three and nine months ended September 30, 2024, respectively, associated with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024, for which the lease terms were modified to accelerate expiration of the lease to December 2024. The remaining $4 million of termination fee income will be recognized during the fourth quarter of 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations, but is excluded from Healthpeak's definition of Portfolio Cash Real Estate Revenues and FFO as Adjusted. | |
(4) | The three and nine months ended September 30, 2024 and 2023 includes reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations. | |
(5) | Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. | |
Healthpeak Properties, Inc. Adjusted Funds From Operations In thousands, except per share data | |||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
FFO as Adjusted applicable to common shares | $ | 316,205 | $ | 249,306 | $ | 907,128 | $ | 728,045 | |||||||
Stock-based compensation amortization expense | 3,755 | 3,434 | 11,935 | 10,966 | |||||||||||
Amortization of deferred financing costs and debt discounts (premiums) | 7,408 | 3,054 | 19,247 | 8,828 | |||||||||||
Straight-line rents(1) | (10,346 | ) | (7,279 | ) | (32,891 | ) | (12,710 | ) | |||||||
AFFO capital expenditures | (23,510 | ) | (24,031 | ) | (76,744 | ) | (66,264 | ) | |||||||
Deferred income taxes | 585 | (430 | ) | 2,330 | (933 | ) | |||||||||
Amortization of above (below) market lease intangibles, net | (7,887 | ) | (5,626 | ) | (23,325 | ) | (20,267 | ) | |||||||
Other AFFO adjustments | (1,277 | ) | (1,123 | ) | (4,947 | ) | (1,852 | ) | |||||||
AFFO applicable to common shares | 284,933 | 217,305 | 802,733 | 645,813 | |||||||||||
Distributions on dilutive convertible units and other | 4,576 | 2,340 | 11,671 | 7,026 | |||||||||||
Diluted AFFO applicable to common shares | $ | 289,509 | $ | 219,645 | $ | 814,404 | $ | 652,839 | |||||||
Diluted AFFO per common share | $ | 0.41 | $ | 0.40 | $ | 1.20 | $ | 1.18 | |||||||
Weighted average shares outstanding - Diluted AFFO | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||
_______________________________________ | ||
(1) | The nine months ended September 30, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This activity is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations. | |
Contacts
Andrew Johns, CFA
Senior Vice President - Investor Relations
720-428-5400
